Loading clinical trials...

Multiple Dose Japanese Bridging Study | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Multiple Dose Japanese Bridging Study

Randomized, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-708163 125 mg in Healthy Japanese and Non-Japanese Subjects

NCT01057030•Bristol-Myers Squibb

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the safety and tolerability of multiple oral daily doses of BMS-708163 in healthy young male subjects

Eligibility

Age

20 - 45 years

Sex

MALE

Healthy Volunteers

Yes

Inclusion Criteria

•Healthy Japanese and non-Japanese subjects
•Japanese subjects must be first generation Japanese and must demonstrate both maternal and paternal Japanese ancestry
•Non-Japanese subjects must not be of Japanese or Asian descent, ie, neither parent nor grandparent was born in Japan or in any Asian country
•BMI of 19 to 25 kg/m², for Japanese and non-Japanese subjects
•Men ages 20 to 45 years

Exclusion Criteria

•Serum creatinine values above the normal range
•Urine protein or blood levels above the normal range
•Liver function tests above the normal range
•TSH, free T3, or free T4 outside the normal range
•Amylase or lipase levels above the normal range
•Positive Fecal Immunochemical Test (FIT™)

Locations (1)

California Clinical Trials Medical Group

Glendale, California, United States

Key Dates

Start Date

March 1, 2010

Primary Completion Date

June 1, 2010

Completion Date

June 1, 2010

Last Updated

January 25, 2011

Enrollment

ACTUAL participants

Conditions

Alzheimer Disease

Interventions

BMS-708163

DRUG

Placebo

DRUG

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

NCT07178210

Alzheimer DiseaseLymphatic Obstruction

View study

RECRUITINGEARLY_PHASE1

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive SymptomsDepression+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 25, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Multiple Dose Japanese Bridging Study

Inclusion Criteria

Exclusion Criteria

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Longitudinal Early-onset Alzheimer's Disease Study Protocol

A Study of AMDX-2011P in Participants With Alzheimer's Disease